Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin II vs Standard Vasopressors in Cirrhotic Patients With Vasodilatory Shock
NCT07568275Phase 1Active, not recruiting
- Sponsor
- Cleveland Clinic
- Start
- Nov 2024
- Primary completion
- Jan 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in vasodilatory shock and septic shock comparing Angiotensin II with Standard of Care (2 arms). Primary endpoint: Change in arterial elastance at 24 hours. Started Nov 2024; status: active, not recruiting.
02
Drugs
Angiotensin II
03
Conditions
vasodilatory shockseptic shock
Beyond the preview
Go deeper on NCT07568275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07568275.